STOCK TITAN

BCDA insiders report 4.99% stake via warrants; blocker provisions limit ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.

Positive

  • Clear disclosure of beneficial ownership totaling 557,179 shares (4.99%)
  • Blocker provisions in warrants that prevent inadvertent crossing of the 4.99% ownership threshold
  • Joint filing and certification stating holdings were not acquired to influence control

Negative

  • Potential dilution exists from additional warrants and shares referenced, although exercise is restricted by blockers
  • Material details missing: the filing references a Securities Purchase Agreement and SPA closing issuances but does not disclose economic terms or pricing in this Schedule 13G

Insights

TL;DR: Reporting persons hold 4.99% via warrants and issuable shares; blocker provisions limit ownership above 4.99%.

The Schedule 13G discloses that each reporting person beneficially owns 557,179 shares representing 4.99% of outstanding common stock as of September 24, 2025, driven by exercisable warrants tied to a Securities Purchase Agreement. The disclosure clarifies excluded shares and potential aggregate holdings absent blocker provisions, which would increase reported holdings materially. For valuation or dilution analysis, note the multiple warrant tranches and the contingent nature of exercisable shares; the filing does not provide transaction pricing or economic terms of the SPA.

TL;DR: This is a standard passive ownership disclosure with explicit blocker provisions and a certification of non-control intent.

The reporting parties filed a joint Schedule 13G, indicating passive intent and certifying the securities were not acquired to change control. The inclusion of blocker provisions in warrants is important governance detail: it limits voting/dispositive power escalation and preserves the reporting persons' status below control thresholds. The filing includes a joint filing agreement as an exhibit, confirming coordinated reporting but not necessarily coordinated action to influence issuer control.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Mitchell P. Kopin
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin
Date:09/24/2025
Daniel B. Asher
Signature:/s/ Daniel B. Asher
Name/Title:Daniel B. Asher
Date:09/24/2025
INTRACOASTAL CAPITAL, LLC
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin, Manager
Date:09/24/2025
Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

How many BioCardia (BCDA) shares do the reporting persons beneficially own?

Each reporting person is reported as beneficially owning 557,179 shares, representing 4.99% of the class as of September 24, 2025.

What limits prevent the reporting persons from owning more than 4.99%?

Intracoastal Warrant 1 and Intracoastal Warrant 2 contain blocker provisions that bar exercise to the extent such exercise would cause beneficial ownership to exceed 4.99%.

Were these securities acquired to influence control of BioCardia?

No. The filers certified that, to the best of their knowledge and belief, the securities were not acquired to change or influence control of the issuer.

Who filed this Schedule 13G for BCDA?

This Schedule 13G was filed on behalf of Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital, LLC.

Does the filing disclose the economic terms of the Securities Purchase Agreement?

No. The Schedule 13G references the SPA and issuances but does not disclose pricing or other economic terms
Biocardia Inc

NASDAQ:BCDA

BCDA Rankings

BCDA Latest News

BCDA Latest SEC Filings

BCDA Stock Data

13.27M
7.70M
18.98%
5.25%
3.61%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SUNNYVALE